The National Medical Products Administration (NMPA) of China has officially approved pretomanid, developed by Shenyang Hongqi Pharmaceutical Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196). This approval marks a significant advancement in the treatment of drug-resistant tuberculosis (TB) patients.
Innovative Mechanism of Action
Pretomanid is a groundbreaking antimycobacterial drug derived from nitroimidazole, designed specifically to combat mycobacterial infections. The drug operates through multiple mechanisms of action, demonstrating bactericidal activity in both aerobic and anaerobic environments. Initially approved in the United States in 2019, pretomanid is used in combination with bedaquiline and linezolid for patients suffering from highly drug-resistant tuberculosis.
Global Reach and Licensing Agreement
Since its initial approval, pretomanid has gained recognition in over 60 countries and regions, including mainland China, Hong Kong, and Taiwan. The drug was originally developed by the non-profit organization TB Alliance and was licensed to Fosun Pharma through a strategic agreement in January 2020. Shenyang Hongqi Pharmaceutical subsequently acquired the rights to distribute pretomanid within China.-Fineline Info & Tech
